GE HealthCare

Current directors and officers who also hold a role at another S&P 500 company.

• Kevin LoboPH · DirectorSYK · CEO
• Anne T. MaddenHONA · Officer
• Catherine A. LesjakGE · Director
• Frank R. JimenezHII · Director
• H. Lawrence Culp, Jr.GE · CEO
• James SaccaroZTS · CFO
• Peter J. ArduiniBMY · Director
• William K. GroganXYL · CFO

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Nov 5, 2026

   ; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 4, 2026, Taha Kass-Hout notified GE HealthCare Technologies Inc. (“GE HealthCare”) that he will resign as Chief Science and Technology Officer. Mr. Kass-Hout’s last day at GE HealthCare will be December 31, 2026.

   Read the 8-K filing
2. Oct 28, 2026

   On October 22, 2026, Jeannette Bankes notified GE HealthCare that she will resign as President and CEO, Patient Care Solutions. Ms. Bankes' last day at GE HealthCare will be November 15, 2026.

   Read the 8-K filing
3. Sep 22, 2026

   On September 22, 2026, the Board of Directors (the “Board”) of GE HealthCare Technologies Inc. (the “Company”) appointed Pascal Desroches to serve as a director of the Company, effective January 4, 2027. The Board also appointed Mr. Desroches as a member of the Audit Committee and the Talent, Culture, and Compensation Committee of the Board, effective January 4, 2027. Upon joining the Board, Mr. Desroches will receive compensation in accordance with the Company’s compensation program for non-employee directors, which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 19, 2026. The Company will also enter into an indemnification agreement with Mr. Desroches.

   Read the 8-K filing
4. Aug 18, 2026

   On August 13, 2026, the Board of Directors (the “Board”) of GE HealthCare Technologies Inc. (“GE HealthCare”) appointed William K. Grogan as Chief Financial Officer, effective September 14, 2026. George A. Newcomb, who currently serves as GE HealthCare’s interim Chief Financial Officer, will cease serving in that interim role on September 14, 2026, and will continue serving as GE HealthCare’s Controller and Chief Accounting Officer. Mr. Grogan, age 48, has served as Executive Vice President and Chief Financial Officer of Xylem Inc., a global water solutions company, since October 2023. Previously, Mr. Grogan served as Senior Vice President and Chief Financial Officer of IDEX Corporation, a global engineered products company, from January 2017 until September 2023. On August 13, 2026, the Talent, Culture, and Compensation Committee (the “Committee”) of the Board approved Mr.

   Read the 8-K filing
5. Jul 23, 2026

   On July 21, 2026, James K. (Jay) Saccaro notified GE HealthCare that he will resign as Chief Financial Officer for a role outside of the medical technology industry. Mr. Saccaro’s last day at GE HealthCare will be August 14, 2026. On July 23, 2026, GE HealthCare named George Newcomb, Controller and Chief Accounting Officer, as interim Chief Financial Officer, effective August 14, 2026. Mr. Newcomb will continue to serve as Controller and Chief Accounting Officer. GE HealthCare has commenced a search for a permanent successor. Mr. Newcomb, age 59, served as the Controller of the healthcare business of General Electric Company (“GE”) beginning in February 2016 and was named as Controller and Chief Accounting Officer of GE HealthCare in January 2023 in connection with the spin-off of GE HealthCare from GE.

   Read the 8-K filing
6. Mar 17, 2026

   On March 13, 2026, the Board of Directors (the “Board”) of GE HealthCare Technologies Inc. (the “Company”) appointed Kevin A. Lobo to serve as a director of the Company, effective immediately. Mr. Lobo’s term will expire at the Company’s 2026 Annual Meeting of Stockholders. The Board also appointed Mr. Lobo as a member of the Talent, Culture, and Compensation Committee of the Board, effective immediately. Mr. Lobo will receive compensation in accordance with the Company’s compensation program for non-employee directors, which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 10, 2025. The Company will also enter into an indemnification agreement with Mr. Lobo.

   Read the 8-K filing
7. Jul 24, 2025

   On July 23, 2025, Lloyd W. Howell, Jr. notified GE HealthCare Technologies Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective immediately. Mr. Howell’s resignation from the Board was not a result of any disagreement on a matter related to the Company’s operations, policies, or practices.

   Read the 8-K filing
8. Apr 15, 2024

   On April 9, 2024, Jan Makela, Chief Executive Officer, Imaging, notified GE HealthCare Technologies Inc. (the “Company”) that he will be resigning from his role at the Company to become the chief executive officer of a private company that is not one of the Company’s competitors. The Company will evaluate internal and external candidates to fill the Chief Executive Officer, Imaging role. Mr. Makela’s last day at the Company will be July 8, 2024.

   Read the 8-K filing
9. Feb 5, 2024

   On January 31, 2024, Betty D. Larson, Chief People Officer, notified GE HealthCare Technologies Inc. (the “Company”) that she will be resigning from her role at the Company and that her last day at the Company will be March 21, 2024.

   Read the 8-K filing
10. May 9, 2023

    On May 4, 2023, GE HealthCare Technologies Inc. (“GE HealthCare” or “we”) named James K. (Jay) Saccaro our Vice President and Chief Financial Officer, effective June 1, 2023. Mr. Saccaro will replace Helmut Zodl, who will cease to be our Chief Financial Officer and will become our Global Vice President, Special Projects and TSA Separation, effective June 1, 2023. Mr. Saccaro, age 50, has served as Chief Financial Officer of Baxter International Inc. (“Baxter”) since July 2015. He held a variety of positions of increasing responsibility at Baxter from 2002 through 2013, including Vice President of Financial Planning and Analysis, Vice President of Finance for Baxter’s operations in Europe, the Middle East and Africa, Vice President of Strategy, and Corporate Vice President and Treasurer. Mr. Saccaro served as Senior Vice President and Chief Financial Officer of Hill-Rom Holdings, Inc.

    Read the 8-K filing
11. Mar 24, 2023

    Severance and Change in Control Benefits for CEO and Leadership Team On March 23, 2023, the Talent, Culture, and Compensation Committee (the “Committee”) of the Board of Directors of GE HealthCare Technologies Inc. (the “Company”) approved the GE HealthCare US Severance and Change in Control Plan for CEO and Leadership Team (the “Plan”), effective April 1, 2023. Prior to April 1, 2023, the Company’s chief executive officer (“CEO”) and US members of the Company’s leadership team, consisting of executives reporting solely to the CEO (the “Leadership Team”), participated in the GE HealthCare US Executive Severance Plan. Effective April 1, 2023, the GE HealthCare US Executive Severance Plan will no longer cover any executive officer of the Company.

    Read the 8-K filing
12. Mar 3, 2023

    The Talent, Culture, and Compensation Committee (“Committee”) of the Board of Directors of GE HealthCare Technologies Inc. (“Company,” “we,” or “our”) made annual awards for 2023, including to the Company's executive officers, on March 1, 2023 ("Grant Date"). The awards were made under the Company’s 2023 Long-Term Incentive Plan for our executive officers and other leaders of the Company, including our chief executive officer ("CEO") and our named executive officers (“NEOs”). The awards to our CEO and NEOs are comprised of three components. Performance stock units (“PSUs”) are tied to preset financial goals, and may be modified by our total shareholder return performance relative to our peer group. These awards vest following a three-year performance period if the grantee remains employed on the vesting date, and they are eligible to vest between 0% to 200% of the target PSUs granted.

    Read the 8-K filing
13. Feb 3, 2023

    Founders Grants The Talent, Culture, and Compensation Committee (the “Committee”) of the Board of Directors of GE HealthCare Technologies Inc. (the “Company”) approved the grant of one-time equity awards (the “Founders Grants”) on February 1, 2023 to approximately 8,200 leaders of the Company, including the Company’s chief executive officer (“CEO”) and the Company’s named executive officers who are currently employed by the Company (“NEOs”), in recognition of the pivotal role leadership will play at a critical time following the Company’s spin-off as a standalone public company.

    Read the 8-K filing
14. Jan 4, 2023

    Director Appointments As previously reported in the Information Statement, which is included as Exhibit 99.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission (the “Commission”) on December 8, 2022, on or prior to January 3, 2023, the persons set forth in the table below assumed their positions as directors on our board of directors (“Board”). Also, on or prior to January 3, 2023, Rodney F. Hochman, Lloyd W. Howell, Jr., Catherine Lesjak (Chair), Anne T. Madden, and William J. Stromberg assumed positions as members of the Audit Committee of the Board; Lloyd W. Howell, Jr. Tomislav Mihaljevic, William J. Stromberg (Chair), and Phoebe L. Yang assumed positions as members of the Talent, Culture, and Compensation Committee of the Board; and Rodney F. Hochman, Risa Lavizzo-Mourey (Chair), Anne T. Madden, Tomislav Mihaljevic, and Phoebe L.

    Read the 8-K filing
15. Dec 14, 2022

    On December 13, 2022, the sole manager of the board of managers (the “Board”) of GE Healthcare Holding LLC (the “Company”) appointed Catherine Lesjak and Michael J. Holston to serve as managers of the Board, increasing the size of the Board from one manager to three managers, effective as of December 14, 2022. Upon her appointment, Ms. Lesjak was named as a member of the Company’s Audit Committee, Talent, Culture, and Compensation Committee, and Nominating and Governance Committee. It is expected that Ms. Lesjak will continue to serve as a member of the Board and the Audit Committee as of and following the effective time of the previously announced distribution of at least 80.1% of the shares of the Company’s common stock by General Electric Company (“GE”) to holders of GE common stock on a pro rata basis (the “Spin-Off”). It is expected that Mr. Holston and Mr.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.